Pharmaceuticals, Biotechnology and Life Sciences
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a…
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex…
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval…
NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) —…
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung…
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing,…
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company…
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q…
Affluent Medical, a French medtech company at the forefront of developing advanced implantable devices, has reached a key milestone in its mission to improve men’s healthas by successfully completing the pilot phase of its clinical study for the Artus system, an innovative artificial urinary sphincter (AUS) designed to treat stress urinary incontinence in men.
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing…